Scarica l'app Stockscreener
43.04
1.03%
0.44
Dopo l'orario di chiusura:
43.25
0.21
+0.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$42.60
Aprire:
$42.7
Volume 24 ore:
3.88M
Relative Volume:
1.32
Capitalizzazione di mercato:
$11.74B
Reddito:
$2.17B
Utile/perdita netta:
$521.27M
Rapporto P/E:
24.32
EPS:
1.77
Flusso di cassa netto:
$633.79M
1 W Prestazione:
+1.53%
1M Prestazione:
+11.65%
6M Prestazione:
+18.05%
1 anno Prestazione:
+107.12%
Intervallo 1D:
$42.22
$43.13
Intervallo di 1 settimana:
$42.21
$43.75
Portata 52W:
$21.18
$48.85
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Confronta EXEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
43.04 | 11.56B | 2.17B | 521.27M | 633.79M | 1.77 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Transcript : Exelixis, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 02 - marketscreener.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort - MSN
Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress By Investing.com - Investing.com South Africa
Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress - Investing.com Australia
Deutsche Bank AG Has $1.54 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Insider Sell: Tomas Heyman Sells Shares of Exelixis Inc (EXEL) - GuruFocus
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) - Yahoo Finance
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy? - Yahoo Finance
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business - Yahoo Finance
Product Performance, Big Money Lift Exelixis - Yahoo Finance
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 - BioSpace
Exelixis reports promising kidney cancer trial results - Investing.com Australia
Exelixis EVP Haley Patrick J. sells $1.5 million in stock By Investing.com - Investing.com Nigeria
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-0 - GuruFocus
Exelixis EVP Haley Patrick J. sells $1.5 million in stock - Investing.com
Exelixis Executives Engage in Significant Stock Transactions - TradingView
Exelixis reports promising kidney cancer trial results By Investing.com - Investing.com India
Exelixis (EXEL) Reports Promising Results from STELLAR-002 Renal Cancer Trial | EXEL Stock News - GuruFocus
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 | EXEL Stock N - GuruFocus
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June | EXEL Stock News - GuruFocus
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June - New Castle News
Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com
Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth - Yahoo Finance
Exelixis, Inc.: A Strategic Buy on Positive Momentum - marketscreener.com
Transcript : Exelixis, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 10 - marketscreener.com
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio? - Benzinga
Citigroup Boosts Exelixis (NASDAQ:EXEL) Price Target to $56.00 - Defense World
Exelixis raises 2025 revenue guidance by $100M amid strong CABOMETYX market share gains and new NET approval - MSN
Exelixis director George Poste sells $948,957 in stock - Investing.com Australia
Exelixis director George Poste sells $948,957 in stock By Investing.com - Investing.com UK
Exelixis Stock Price, Quotes and Forecasts - Benzinga
Exelixis (NASDAQ:EXEL) Stock Price Up 5.7% After Analyst Upgrade - Defense World
Exelixis Q1 2025 Earnings Call Highlights Growth - TipRanks
Guggenheim Raises Price Target for Exelixis (EXEL) Amid Strong R - GuruFocus
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line - MSN
Demystifying Exelixis: Insights From 8 Analyst Reviews - Benzinga
Exelixis (EXEL) Target Price Raised by Citigroup Analyst | EXEL Stock News - GuruFocus
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Citi Elevates Price Target for Exelixis (EXEL) to $56 Amid Stron - GuruFocus
Guggenheim Raises Price Target for Exelixis (EXEL) Amid Strong Revenue Forecast | EXEL Stock News - GuruFocus
Exelixis (EXEL) Receives Increased Price Target, Maintains Stron - GuruFocus
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):